Page last updated: 2024-09-03

imatinib mesylate and Cancer of the Uterus

imatinib mesylate has been researched along with Cancer of the Uterus in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (66.67)	29.6817
2010's	3 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kamel, M; Kristiansen, G; Montemurro, M; Trojan, A	1
Alvarez, RD; Birrer, MJ; Boggess, JF; Darcy, KM; Elias, KM; Hoffman, JS; Huh, WK; Long, HJ; O'Malley, DM; Sill, MW	1
Cheung, WY; Ksienski, D	1
Chang, H; Liu, WP; Ma, HB; Wang, YC; Xu, X; Zeng, F	1
Amunni, G; Paglierani, M; Raspollini, MR; Taddei, A; Taddei, GL; Villanucci, A	1
Amunni, G; Paglierani, M; Pinzani, P; Raspollini, MR; Simi, L; Taddei, GL; Villanucci, A	1
Dushkin, H; Schilder, RJ	1
Broaddus, RR; Caudell, JJ; Deavers, MT; Gershenson, DM; Lu, KH; Ramondetta, LM; Slomovitz, BM	1
Abad, M; Bullón, A; de Alava, E; Hernández, T; Herrero, D; Mackintosh, C; Martins, AS; Orfao, A; Pérez, A; Pérez-Fontán, J; Serrano, C; Serrano, E	1

Reviews

1 review(s) available for imatinib mesylate and Cancer of the Uterus

Article	Year
Imatinib mesylate and its potential implications for gynecologic cancers. Current treatment options in oncology, 2005, Volume: 6, Issue:2 Topics: Benzamides; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Imatinib Mesylate; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome; Uterine Neoplasms	2005

Article

Year

Imatinib mesylate and its potential implications for gynecologic cancers.

Current treatment options in oncology, 2005, Volume: 6, Issue:2

Topics: Benzamides; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Imatinib Mesylate; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Survival Analysis; Treatment Outcome; Uterine Neoplasms

2005

Trials

1 trial(s) available for imatinib mesylate and Cancer of the Uterus

Article	Year
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecologic oncology, 2010, Volume: 117, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinosarcoma; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome; Uterine Neoplasms	2010

Article

Year

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.

Gynecologic oncology, 2010, Volume: 117, Issue:2

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinosarcoma; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome; Uterine Neoplasms

2010

Other Studies

7 other study(ies) available for imatinib mesylate and Cancer of the Uterus

Article	Year
Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:11 Topics: Aged; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sarcoma; Uterine Neoplasms	2009
Metastatic uterine leiomyosarcoma and eosinophilia. Obstetrics and gynecology, 2011, Volume: 117, Issue:2 Pt 2 Topics: Antineoplastic Agents; Benzamides; Dyspnea; Eosinophilia; Fatal Outcome; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Middle Aged; Piperazines; Prednisone; Pyrimidines; Splenic Neoplasms; Uterine Neoplasms	2011
Successful treatment of mast cell sarcoma of the uterus with imatinib. International journal of hematology, 2011, Volume: 94, Issue:5 Topics: Adult; Antineoplastic Agents; Benzamides; Female; Genes, abl; Humans; Imatinib Mesylate; Mast-Cell Sarcoma; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Uterine Neoplasms	2011
C-kit expression in uterine leiomyosarcomas: an immunocytochemical study of 29 cases of malignant smooth muscle tumors of the uterus. Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Leiomyosarcoma; Middle Aged; Phenotype; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Uterine Neoplasms	2003
c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-15, Volume: 10, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; DNA; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Leiomyosarcoma; Middle Aged; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Treatment Outcome; Uterine Neoplasms	2004
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. Applied immunohistochemistry & molecular morphology : AIMM, 2005, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Benzamides; Female; Gene Expression Profiling; Humans; Imatinib Mesylate; Immunohistochemistry; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma; Uterine Neoplasms	2005
Imatinib is not a potential alternative treatment for uterine leiomyosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jul-01, Volume: 11, Issue:13 Topics: Antineoplastic Agents; Benzamides; Blotting, Western; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Leiomyosarcoma; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Uterine Neoplasms	2005